From the first reported cases of HIV in 1981 to the latest breakthroughs in long-acting prevention, this Spotlight timeline traces key moments in the global and South African response to the virus. It highlights scientific milestones, political controversies, activism, and the human stories that shaped one of the most significant public health challenges of our time.
Spotlight has launched a new HIV dashboard and graph generator based on outputs from the Thembisa model. Our hope is that this dashboard will help the public and people working in healthcare to find important HIV numbers more easily. Please take a look and let us know what you think of it.
A child-friendly formulation of the antiretroviral drug dolutegravir was first included in the country’s HIV treatment guidelines in 2023. New estimates suggest that most children aged one to four living with HIV have now been switched to the drug, reports Elri Voigt.
South Africa still lacks an action plan after the withdrawal of US aid for HIV and related health services. But when funds do arrive, how will they be managed? Russell Rensburg suggests the answer may lie in the District Health Programme Grant.
The sudden and severe US cuts to grants from the world’s largest health research funder threaten to unravel the medical research landscape in South Africa. A crucial question now is whether the government will turn this crisis into an opportunity for renewal, write Marcus Low and Nathan Geffen.
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Elri Voigt reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections.
Amid major disruptions caused by aid cuts from the United States government, the health department aims to enrol a record number – an additional 1.1 million – of people living with HIV on life-saving antiretroviral medicine this year. Experts tell Spotlight it can’t be business as usual if this ambitious programme is to have a chance of succeeding. Ufrieda Ho reports.
Following President Donald Trump’s decision to suspend foreign aid, President Cyril Ramaphosa can display great leadership by meeting with leaders of wealthy countries and convincing them to increase spending to support the health systems of poorer countries, write Nathan Geffen and Marcus Low.
Ahead of World AIDS Day 2024, Professor Salim Abdool Karim and Dr Nikita Devnarain argue that South Africa needs a concerted effort to reduce new HIV infections in young women and to prepare for the rollout of long-acting forms of HIV prevention alongside a well-functioning HIV treatment programme.
Whether or not someone living with HIV in South Africa gets a one- or three-months’ supply of antiretrovirals at a time depends partly on the clinic where they happen to go for HIV care. Ahead of World AIDS Day 2024, Elri Voigt unpacks the legal and policy issues relating to prescriptions and HIV medicine refills and asks why people living with HIV are treated so differently in different parts of the country.
HIV prevention injections that can provide two, or even six, months of protection per shot have arguably been the biggest HIV story of the year. Ahead of World AIDS Day, Professor Francois Venter assesses the state of play and the critical next steps with these potentially game-changing new tools in the fight against HIV.
Once South Africa had closed the door on state-sponsored AIDS denialism in 2008, a critical question was how to offer HIV treatment to as many eligible people as possible as quickly as possible. Given that the health system did not have enough doctors for the job, it was decided in 2010 to rope in nurses to help out. Tiyese Jeranji asks where things stand with Nurse Initiated and Managed Antiretroviral treatment (NIMART) 13 years later.
